What Is ALECT2 Amyloidosis and Who May Be at Risk?

Receiving a diagnosis of a rare disease like ALECT2 amyloidosis can be confusing and overwhelming. ALECT2 amyloidosis is a rare subtype of amyloidosis caused by the buildup of a protein called LECT2, which is naturally produced by the liver ^[1]. Unlike some other forms of the disease, ALECT2 primarily affects the kidneys, though deposits often accumulate in the liver as well ^[2][3]. It is most frequently reported in specific ancestral groups, but it can affect people of any background ^[2][4]. Currently, there is no approved disease-modifying therapy specifically for ALECT2; care focuses on individualized, supportive kidney care ^[2][5].

How ALECT2 Affects the Body

In ALECT2 amyloidosis, the LECT2 protein misfolds into abnormal strands called amyloid fibrils, which deposit in the body’s tissues ^[6][7]. The exact reasons why this happens are still being studied ^[6].

The primary organ impacted is the kidney, leading to a gradual decline in kidney function over time, though the rate of decline varies from person to person ^[8]. In the early stages, kidney disease can be completely silent (asymptomatic). As it progresses, it can cause symptoms like fatigue, high blood pressure, or swelling.

Many patients with ALECT2 have only mild amounts of protein in their urine (proteinuria), and some have none at all, with urine tests showing no active signs of inflammation ^[2][8]. If a patient experiences unusually heavy protein loss (nephrotic-range proteinuria, which often causes low blood protein levels and noticeable swelling), doctors should evaluate them for a second, coexisting kidney condition. While ALECT2 can occasionally cause heavy proteinuria, it is less typical for ALECT2 alone ^[4][9].

The liver is another frequent site for these amyloid deposits ^[3]. However, liver deposits in ALECT2 are generally “silent”—meaning normal liver blood tests do not rule out deposits, but the deposits rarely cause significant liver damage or symptoms ^[8][3]. Clinically significant involvement of the heart or brain is uncommon ^[10][2]. Because of this, patients may not experience the severe heart complications seen in other amyloidosis types, but overall outcomes still depend heavily on kidney function, age, and other health conditions ^[8][10].

Who is at Risk?

ALECT2 amyloidosis is typically diagnosed in older adults, with the average age at diagnosis often in the 60s ^[8][4].

ALECT2 has been frequently reported in specific populations, including:

• Hispanic and Latino populations (particularly people of Mexican descent) ^[2][11].
• Punjabi, Pakistani, and Middle Eastern populations ^[2][4].
• Native American and First Nations populations ^[12].
• Han Chinese populations ^[4].

It is important to know that ancestry is an association, not a diagnosis or proof of inheritance ^[2]. The strength of the evidence differs among these groups, and a person from any background can develop ALECT2. Having one of these backgrounds does not mean you will definitely get the disease. The disease is not known to follow a simple inherited pattern, so having a relative with it does not mean other family members will necessarily be affected ^[1].

Diagnosis and the Importance of Accurate Typing

Because ALECT2 is a lesser-known form of amyloidosis, accurate diagnosis by an experienced pathology center is essential ^[13]. The deposits must be accurately typed (identified) to confirm they are LECT2 proteins ^[2][13].

The most reliable way to confirm ALECT2 is through a specialized protein-identification test called mass spectrometry. Standard tissue staining techniques (like immunohistochemistry) can sometimes give inconsistent results for LECT2 ^[7][13][14].

Misdiagnosing ALECT2 as AL amyloidosis (Light Chain amyloidosis, a type caused by abnormal bone marrow cells) can be dangerous ^[15]. Chemotherapy directed at AL amyloidosis does not treat ALECT2 itself ^[15][16]. However, because two separate conditions can occasionally coexist (such as having ALECT2 alongside a separate blood disorder), appropriate blood and urine tests looking for abnormal proteins should always be performed and interpreted by an experienced hematologist or pathologist before ruling treatments out ^[16].

Current Management and What to Expect

Currently, there is no approved disease-modifying therapy that can stop the production of the LECT2 protein or clear the existing deposits ^[2][5]. Patients should ask their doctors if any clinical trials are available. Management is heavily focused on individualized supportive kidney care led by a nephrologist (kidney specialist) and, when available, an amyloidosis center:

• Monitoring kidney function: Doctors will regularly check your eGFR (estimated Glomerular Filtration Rate, a number estimating how well your kidneys filter waste), your urine protein levels, and your blood potassium ^[8][17]. The frequency of these tests is individualized.
• Medication management: Managing blood pressure is key. Doctors may prescribe kidney-protective medications like ACE inhibitors or ARBs. However, these medications are not appropriate for everyone and can affect kidney function and potassium levels; they should never be started, stopped, or adjusted without a clinician’s guidance ^[18][19].
• Avoiding kidney injury: Patients should discuss all medications with their doctor, specifically avoiding nonsteroidal anti-inflammatory drugs (NSAIDs, like ibuprofen), which can cause acute kidney injury ^[18][20].
• Preparing for the future: Kidney function may remain stable for some, but others will see a substantial decline. If a patient reaches advanced kidney failure, treatments like dialysis or a kidney transplant become necessary ^[8][21]. A kidney transplant is considered a reasonable and successful option for ALECT2, and while the disease can occasionally appear in the new organ, patients often maintain good function for years ^[11][22][23].

When to Seek Immediate Help:
While monitoring is usually routine, you should contact your care team urgently if you experience markedly reduced urination, rapidly worsening swelling in your legs or body, severe shortness of breath, or sudden confusion.